Health

Anupam Mittal (Shark Tank) Cautions on Fitness Shortcuts: 'Ozempic for Weight Loss Could Become Like Eno If...'

Reviewed by Dr. Adrian Vale, MDInternal Medicine · Board-Certified Obesity Medicine

·December 16, 2025·1 min read

Anupam Mittal raised concerns about the potential overuse of drugs like Ozempic for weight loss. He also highlighted the upcoming expiration of key GLP-1 drug patents, possibly leading to market changes.

Anupam Mittal Cautions Against Weight Loss Shortcuts

Mittal indicated that the drug, currently priced around ₹8,800 monthly in India, might generate an annual market nearing ₹1,000 crore, according to industry projections.

Mittal also emphasized a significant shift expected in the pharmaceutical industry. The expiration of crucial GLP-1 drug patents, starting in March 2026, could pave the way for cheaper alternatives from Indian pharmaceutical firms. This, he proposed, might spark quick industry growth, potentially increasing the weight-loss drug market substantially in the years ahead. Companies like Cipla, he observed, seem suitably prepared for entering this market. Health tracking apps like Shotlee can help monitor health changes, but are not a substitute for healthy lifestyle choices.

Source Information

Originally published by mint.Read the original article →

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Health & Wellness

Ozempic and Male Fertility: Can Semaglutide Boost Sperm Quality?

Emerging research indicates that GLP-1 medications, including Ozempic and Mounjaro, may offer unexpected benefits for male reproductive health by addressing underlying metabolic issues.

7 min read

Health & Wellness

Semaglutide and Male Fertility: New Study Reveals Testosterone Boost

Can GLP-1 medications like Ozempic or Wegovy improve male fertility? A new study indicates potential benefits for testosterone and sperm health, but what does this mean for patients?

7 min read

Health & Wellness

Semaglutide and Blood Pressure Meds: Why Dizziness Risk Is Rising

A new study reveals a potential safety concern when combining GLP-1 medications with blood pressure drugs, highlighting the importance of monitoring hypotensive episodes in select patients.

8 min read

Same topic: weight loss

All weight loss articles →

Health & Wellness

Wegovy, Zepbound & More: Hers Makes GLP-1s Accessible from $39

The journey to weight loss can be challenging, and for many, advanced medications like GLP-1 injectables offer a crucial pathway. However, their high cost often presents a significant barrier. Hers is changing this landscape by making popular GLP-1 and other weight loss treatments more accessible and affordable than ever before.

7 min read

Medical News

Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise

Eli Lilly has released pivotal Phase 3 trial data for retatrutide, a triple agonist showing up to 28% body weight reduction and significant improvements in diabetes and sleep apnea.

7 min read

Medical Insights

Beyond GLP-1s: Unlocking Better Diabetes Control with Korlym

For individuals struggling with difficult-to-control type 2 diabetes and weight management, even powerful GLP-1 medications might not be enough. New research highlights the significant role of hypercortisolism and the promising potential of Korlym in optimizing treatment outcomes.

6 min read

More in Health

Health & Wellness

GLP-1s & Telehealth: Navigating Risks and Ensuring Safety

The booming popularity of GLP-1 medications for weight loss has coincided with a dramatic rise in telehealth services. This article delves into the benefits and significant risks of obtaining these powerful drugs online, highlighting critical safety concerns and offering guidance for patients.

6 min read